CD274 and chronic myelogenous leukemia, BCR-ABL1 positive: PD-L1 has been reported to directly enhance cancer cell survival and tumor progression, in addition to its immunosuppressive function77–79, indicating that the PD-L1 blockade itself is detrimental to CML LSCs.